Background
In 2001, an estimated 177 million adults (20-79 years) worldwide have diabetes. Type 2 diabetes (T2D) constitutes 85-95% of all diabetics in developed countries and accounts for an even higher percentage in the developing countries [1] like India. Asian Indians with T2D, in particular, are more prone to develop diabetic nephropathy [2] . Type 2 diabetes has become the single most common cause of end-stage renal disease (ESRD), accounting for 40% of new cases of ESRD with an estimated cost in excess of US$15.6 billion [3] for treatment.
The role of greater glycemic exposure resulting in overt nephropathy in T2D is poorly understood. Genetic factors, which may increase the susceptibility to nephropathy in patients with diabetes, have been proposed. A range of linkage studies of familial aggregation of diabetic nephropathy in type 1 or 2 diabetes indicates that potential genetic determinants have larger effects not amenable for detection by conventional genetic techniques [4] . Major breakthroughs in finding genetic susceptibility factors in diabetic nephropathy remain elusive.
Type 2 diabetes is a polygenic and complex disease. Earlier studies to examine the molecular mechanisms that underlie the origin and progression of diabetic nephropathy have been limited, in part because conventional research tools have restricted investigators to focus on single genes or isolated pathways [5] . Several genes such as, nephrin [6] , NAD(P)H oxidase and RAGE (receptor for advanced glycation end product) [7] , toll-like receptor TLR4 gene [8] , ACE (Angiotensin converting enzyme) [ diabetes through these studies. Some of these genes were also identified in the present study.
Genomic approaches to determine differential expression profiles utilizing serial analysis of gene expression (SAGE) [18] and DNA microarrays [19] are now providing global views of the potential genes and pathways that are associated with diabetes. Utilizing these approaches, tissue-specific gene expressions in human pancreas, muscle and fat demonstrated differential regulation of approximately 800 genes in diabetes [19] . Gene expression profiling in diabetic nephropathy has previously been performed only in animal models [20, 21] .
The relationship between white blood cells (WBCs) and diabetic vasculopathy is well described and elevated WBC count, even within the normal range, is strongly associated with both macro-and microvascular complications in type 2 diabetes. Immunological changes mediated by WBCs, such as chronic inflammation [22, 23] , infiltration of lymphocytes and macrophages by advanced glycation endproducts (AGEs) [24] and autoantibodies [25, 26] were demonstrated to play a role in the pathogenesis of diabetic nephropathy. Peripheral blood mononuclear cells express enzymes such as manganese superoxide dismutase, CuZn superoxide-dismutase and glutathione peroxidase which can protect against oxidant damage. Dysregulation of antioxidant enzyme activity in blood cells was demonstrated to increase the flux of glucose through the polyol pathway and generation of excess reactive oxygen species (ROS), leading to tissue damage and contributing to early diabetic renal disease [17] .
Even though extensive literature exists relating peripheral blood cells to diabetic complications, the association of gene expression changes in PBCs in insulin homeostasis compared to target tissue such as pancreas is largely unknown. In this study, we examined gene expression profiles of peripheral blood cells in type 2 diabetes with and without nephropathy to identify potential gene signatures that could detect nephropathy.
We compared the changes in PBCs with previous studies of global gene expression changes in endocrine pancreas and skeletal muscle to provide new insights into molecular mechanisms underlying diabetic nephropathy.
Results and discussion

Global gene expression changes in type 2 diabetes
Profiling of 13,824 human cDNAs using RNA extracted from peripheral blood cells of subjects with type 2 diabetes and nephropathy showed statistically significant changes in 420 genes (complete list in additional data file 1), less than 2% of the cDNAs profiled.
Comparison of T2D and T2DN with control subjects revealed a similar magnitude of regulatory response with number of genes perturbed in each disease state, 142 genes in T2D vs. 158 genes in T2DN (table 1). As shown in figure 1a, 109 and 125 genes were uniquely regulated in type T2D and T2DN, respectively. Thirty three genes were commonly regulated in T2D and T2DN when compared to control subjects. The detection of significant number of genes uniquely changed in T2D or T2DN suggests that distinct subsets of genes are involved in these two variable states in diabetes. Hierarchical clustering [27] of the genes significantly regulated in diabetes (420 genes) showed distinct gene clusters that are unique to T2D and T2DN (figure 1b). This demonstrates that gene expression signatures in PBCs could potentially provide a mechanism to distinguish diabetic nephropathy state.
Functional analysis of genes regulated in diabetes
Two thirds of the 420 genes with significant changes in expression in type 2 diabetes and nephropathy in the present study were ESTs (expression sequence tags) or genes with unknown function (complete list in additional data file 1). All named genes with functional annotations in the Unigene database [28] as of January 14, 2004 were categorized by broad functions as shown in figures 2a and 2b. The cell growth and maintenance category was the largest functional category (27%) that was regulated in T2D. This functional category also showed distinct differences between T2D and T2DN, with a smaller number of changes in nephropathy (7% in T2DN compared to 27% in T2D). Other functional categories that showed significant differences between T2D and T2DN are nucleic acid binding (13 vs. 22%), protein biosynthesis (13 vs. 18%) and signal transduction (10 vs.16%). For descriptive purposes, enzymes involved in various cellular processes such as cell cycle, growth and others are represented under the enzymes and metabolism category (table 2) .
Changes in genes regulating energy metabolism/enzymes
Metabolic homeostasis is long considered a major component in pathophysiology of diabetes. In PBCs, of the 99 genes encoding for enzymes regulating carbohydrate and fat metabolism, surprisingly only 3 enzymes showed significant differential expression greater than 2 fold change in diabetes or diabetic nephropathy (additional data files 2 and 3). This shows that insulin regulation of energy homeostasis in PBCs is distinctly different from target tissue such as skeletal muscle and pancreas. The genes encoding metabolic enzymes (i.e., protein phosphatase 2A, glutamic-oxaloacetic transaminase and calmodulin 3) that showed significant differential expression ( shown to be associated with diabetic nephropathy in specific populations [13] with a predisposition to ESRD. Cytochrome P450 that is significantly downregulated in T2DN, is an important member in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens and estrogens with important implications in metabolic regulation of insulin homeostasis.
Genes related to signal transducer and cell cycle
Immunoregulation plays a significant role in diabetes and pathogenesis of nephropathy.
Regulation of interleukin 2 (IL2) receptor gamma chain (IL2RG), interleukin 17 receptor B (IL-17BR) and chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant) detected in
PBCs correlates well with previous studies on their role in T2D and particularly T2DN. 
Interleukin 2 (IL2) receptor gamma chain (IL2RG)
Genes regulated in protein catabolism, ubiquitin-proteasome pathway
Ubiquitin-proteasome regulating protein degradation mediates several biological processes such as transcriptional regulation, cell cycle control, antigen processing, apoptosis and DNA repair. Insulin is known to influence many of these mechanisms potentially through proteasome inhibition or activation. Insulin and IGF-1 promote ubiquitin-proteasome mediated degradation of insulin receptor substrates-1 and 2, an important complex system involved in insulin action and B-cell survival [41, 42] . Direct interaction of the glucose transporters (Glut) 1 and 4 and Glut4 with members of ubiquitin family, has been shown to play an important role in the control of glucose uptake [43] . Ubiquitin-proteasome also plays a major role in diabetes induced protein wasting and skeletal muscle loss [19] .
In this study, significant number (8) figure 3 . In the present study, the expression level of 2 mRNAs of the ubiquitin-conjugating enzymes increased and 6 mRNAs of the proteasome components decreased in diabetic nephropathy (additional data file 4). The ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) gene known to catalyze the ubiquitination of histones, plays a major role in transcription regulation. In chronic renal failure (CRF), the ATP-dependent, ubiquitin-proteasome proteolytic pathway is activated with increases in the transcription of genes encoding proteins of this pathway. Endocrine abnormalities in CRF (e.g., insulin resistance) could also upregulate proteasome activity and contribute to muscle protein wasting in CRF [47] . Ubiquitin-proteasome pathway was also shown to be significantly regulated in gene profiling study of human skeletal muscle [19] .
Genes with significant regulation in diabetic nephropathy
Diabetic nephropathy is the leading cause of ESRD, yet the molecular mechanisms underlying this diabetic complication are poorly understood. To identify potential genes reflective of diabetic nephropathy state, first we compared expression profiles of T2DN with control normal subjects. This direct comparison revealed significant differential expression of a set of 158 genes (table 1). In order to subset genes that are associated with diabetes and shared in T2DN, we compared diabetics with nephropathy and diabetics without nephropathy and identified that 262 genes were regulated in this comparison (table 1 and figure 1a). As shown in figure 1a, 48 genes were commonly regulated in both comparisons (T2DN vs. C and T2DN vs. T2D) suggesting that they were uniquely regulated in nephropathy. Among these 48 genes, 16 were ESTs with unknown functions; others with known function are listed in table 3. Of the 32 known genes, 9
were described in literature as associated with diabetes or related kidney disease. Whole genome scanning of families with multiple members affected with diabetes has identified chromosome regions 1q, 12q and 20q to likely harbor type 2 diabetes gene.
[60]. In the present analysis, there were 45 genes, which were preferentially expressed in either of the groups of diabetes vs. controls in peripheral blood cells that were mapped to these chromosomal regions (additional data file 8). Further investigations on some of these target genes could provide new evidence for genetic contribution in diabetes and underlying mechanisms.
Conclusion
During the past few years, microarrays have greatly facilitated obtaining global views of gene expression changes to compare phenotypic changes or response to stimulus.
Although these arrays were not specifically geared to represent tissues and pathways known to be affected by diabetes, they have been used in both type 1 and type 2 diabetes research [61] . This is the first study to examine the changes in peripheral genome to identify novel candidates in the development of diabetes and diabetic nephropathy. The present investigation examined gene expression at a single time-point and it is likely that the nature and extent of gene expression vary depending on many other parameters during the progression of diabetes. Moreover, expression data in microarray study, i.e., mRNA levels, may not accurately reflect protein levels, and expression of a protein may not always have a physiological or pathological consequence. However, the identification of candidate genes on the basis of quantification of their expression level and the subsequent application of this knowledge to disease gene identification and target manipulation, is a logical step toward realization of the new genes-to-mechanisms paradigm [62] . 
Methods Subjects
Peripheral blood cells collected from 6 subjects with type 2 diabetes, 6 subjects with diabetic nephropathy and 6 control subjects were used to prepare pooled samples for each group. Selected subjects with T2DN had serum creatinine more than 2.5mg/dL, glomerular function rate reduced by 50% and no other renal pathologies. They were matched with subjects with T2D without nephropathy, who had urine albumin less than 20mg per 1g of creatinine. Control subjects (n=6) without diabetes and renal disease were selected by matching for age and gender with type 2 diabetics. Informed consent was obtained from the subjects following the institution (Nizam's Institute of Medical Sciences, Hyderabad) review board guidelines for human subjects. Total RNA (10 Qg) was reverse transcribed with Superscript II (Invitrogen) using poly-T primer and labelled with Cy5 by an amino-allyl labeling protocol. Each sample was hybridized to two individual arrays. Arrays were scanned using SA5000 fluorescent scanner (Perkin Elmer) and the data collected and analyzed with QuantArray™ software (Perkin Elmer). The detailed microarray protocols and the full data sets are available on our supplemental website [63] . Single channel method was used to avoid dye bias following the Affymetrix and recent Agilent and Codelink protocols. Quality control of duplicate arrays was set to r >0.94 (additional data file 9). The dataset is MIAME compliant; raw and processed data files in MAGE-ML format are available for depositing in a public data repository. Tables   Table 1 Global view of regulated genes in diabetes in peripheral blood cells Table 2 Diabetes regulated genes in peripheral blood cells Table 3 Genes associated with nephropathy in type 2 diabetes mellitus Genes (n=420) with significant expression were normalized by the absolute value of the maximum fold change for the gene and grouped by hierarchical clustering using Euclidean distances. Genes included were statistically significant by z test using a pooled error model, cut-offs were adjusted for multiple comparisons using a false detection rate (FDR) of 0.05. 
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(1.90%) T2D: type 2 diabetes mellitus without nephropathy T2DN: type 2 diabetes mellitus with nephropathy C: controls without diabetes and nephropathy Up-regulated( ): Gene expression levels were significantly higher. Down-regulated( ): Gene expression levels were significantly lower.
Significant regulation of gene expression levels was defined as a fold change between groups (T2D, T2DN, C) of greater than 2 or less than -2 (using a common error model and a modified z test, all 2-fold changes were statistically significant at p<0.05 after FDR correction for multiple comparisons). Venn Diagram of overlap in regulated genes in type 2 diabetes mellitus with and without nephropathy.
T2D: type 2 diabetes mellitus without nephropathy T2DN: type 2 diabetes mellitus with nephropathy C: controls without diabetes and nephropathy
Figure 1b. Global Gene Expression changes in type 2 diabetes mellitus with and without nephropathy
Genes (n=420) with significant expression were normalized by the absolute value of the maximum fold change for the gene and grouped by hierarchical clustering using Euclidean distances. Genes included were statistically significant by z test using a pooled error model, cut-offs were adjusted for multiple comparisons using a false detection rate (FDR) of 0.05. All named genes with functional annotations in the Unigene database were categorized by broad functional class and broad process class
Total genes=142 Known genes=48
Known genes= 44 Total genes=158 
Regulation of Proteasome Pathway in type 2 diabetes mellitus with nephropathy or without nephropathy
The gene expression of components of the ubiquitin-proteasome degradation pathway in type 2 diabetes mellitus with nephropathy or without nephropathy. Color scale represents relative fold change of type 2 diabetes mellitus with nephropathy compared to diabetes without nephropathy. Dark red = T2DN/T2D > 2; Light red = T2DN/T2D > 1; Dark green = T2DN/T2D < -2; Light Green = T2DN/T2D < -1. The GenMAPP-derived proteasome pathway was modified utilizing information from Glickman and Ciechanover and updated with gene symbols from Locuslink. T2D: type 2 dia betes mellitus without nephropathy T2DN: type 2 diabetes mellitus with nephropathy Figure 3 
